AILERON THERAP (NASDAQ:ALRN) - Equities researchers at William Blair issued their Q2 2017 EPS estimates for shares of AILERON THERAP in a report released on Monday. William Blair analyst Y. Xu forecasts that the company will post earnings per share of ($0.42) for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for AILERON THERAP’s Q3 2017 earnings at ($0.32) EPS, Q4 2017 earnings at ($0.35) EPS, FY2017 earnings at ($1.49) EPS and FY2018 earnings at ($1.79) EPS.
Several other analysts also recently weighed in on ALRN. Jefferies Group LLC initiated coverage on shares of AILERON THERAP in a report on Monday. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity initiated coverage on shares of AILERON THERAP in a report on Monday. They issued a “buy” rating and a $19.00 target price for the company. Finally, Bank of America Corporation began coverage on shares of AILERON THERAP in a report on Monday. They issued a “buy” rating and a $19.00 target price for the company.
COPYRIGHT VIOLATION NOTICE: This story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/07/aileron-therap-forecasted-to-earn-q2-2017-earnings-of-0-42-per-share-nasdaqalrn-updated.html.
Shares of AILERON THERAP (ALRN) opened at 13.11 on Wednesday. The company’s market cap is $192.85 million. AILERON THERAP has a 12-month low of $10.73 and a 12-month high of $14.32. The firm has a 50 day moving average price of $12.93 and a 200-day moving average price of $12.93.
In other AILERON THERAP news, major shareholder Cvf, Llc purchased 180,000 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $2,700,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Reinhard J. Ambros purchased 266,667 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,000,005.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 696,667 shares of company stock valued at $10,450,005. Insiders own 68.10% of the company’s stock.
AILERON THERAP Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Receive News & Ratings for AILERON THERAP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AILERON THERAP and related companies with MarketBeat.com's FREE daily email newsletter.
